Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World dupilumab study aims to ease chronic itch

NCT ID NCT05991323

Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 100 adults with prurigo nodularis who are already prescribed dupilumab (Dupixent) by their doctor. Researchers will track why patients start or stop the drug, how well it controls itching and skin bumps, and any hospital visits. The goal is to see how dupilumab performs outside of clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dupilumab (Dupixent)
What this could lead to
If successful, this could confirm dupilumab as a reliable long-term treatment for prurigo nodularis, helping reduce itching and skin nodules.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Dupilumab can cause side effects like injection site reactions or allergic reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Eligible participants who initiate dupilumab treatment for prurigo nodularis (according to the country-specific prescribing information)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years or older at the time of informed consent. * Physician decision to treat the patient with dupilumab for prurigo nodularis (according to the country-specific prescribing information) made prior to and independently of the patient's participation in the study. * Patients able to understand and complete study-related questionnaires. * Patients provide voluntary informed consent to participate in the study before inclusion in the study. Exclusion Criteria: * Patients who have a contraindication to dupilumab according to the country-specific prescribing information label. * Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of visits and assessments. * Patients currently participating in any interventional clinical trial. * Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prurigo nodularis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prurigo nodularis

Contacts and locations

Locations

  • Allergy Center at Brookstone Research - Centricity Research - PPDS- Site Number : 8400025

    Columbus, Georgia, 31904, United States

  • Center for Dermatology Clinical Research- Site Number : 8400002

    Fremont, California, 94538, United States

  • Dawes Fretzin Clinical Research Group-7910 N Shadeland Ave- Site Number : 8400003

    Indianapolis, Indiana, 46250-2041, United States

  • Derm Institute of Western Michigan- Site Number : 8400034

    Caledonia, Michigan, 49316-7478, United States

  • Dermatology Associates Western Michigan- Site Number : 8400033

    Grand Rapids, Michigan, 49546-6204, United States

  • Duke Dermatology Clinic- Site Number : 8400026

    Durham, North Carolina, 27710-4000, United States

  • GSI Clinical Research- Site Number : 8400017

    Margate, Florida, 33063-7011, United States

  • Golden State Dermatology- Site Number : 8400014

    Walnut Creek, California, 94598-3335, United States

  • Halcyon Dermatology- Site Number : 8400023

    Laguna Hills, California, 92653, United States

  • Investigational Site Number : 1240002

    Newmarket, Ontario, L3Y 5G8, Canada

  • Investigational Site Number : 1240003

    Barrie, Ontario, L4M 7G1, Canada

  • Investigational Site Number : 1240004

    Ajax, Ontario, L1S 7K8, Canada

  • Investigational Site Number : 1240005

    Toronto, Ontario, M2M 4J5, Canada

  • Investigational Site Number : 1240006

    Fredericton, New Brunswick, E3B 1G9, Canada

  • Investigational Site Number : 1240007

    Edmonton, Alberta, T5K 2V4, Canada

  • Investigational Site Number : 1240009

    Calgary, Alberta, T2J 7E1, Canada

  • Investigational Site Number : 1240010

    Waterloo, Ontario, N2J 1C4, Canada

  • Investigational Site Number : 1240011

    London, Ontario, N6H 5L5, Canada

  • Investigational Site Number : 1240012

    Surrey, British Columbia, V3R 6A7, Canada

  • Investigational Site Number : 1560002

    Shenzhen, 518000, China

  • Investigational Site Number : 1560003

    Jinan, Shandong, 250001, China

  • Investigational Site Number : 1560004

    Xi'an, Shaanxi, 710004, China

  • Investigational Site Number : 1560005

    Beijing, 100083, China

  • Investigational Site Number : 1560006

    Shanghai, 200020, China

  • Investigational Site Number : 1560007

    Beijing, 100050, China

  • Investigational Site Number : 1560008

    Hangzhou, Zhejiang, 311400, China

  • Investigational Site Number : 1560009

    Guangzhou, Guangdong, 510630, China

  • Investigational Site Number : 1560010

    Wenzhou, Zhejiang, 325000, China

  • Investigational Site Number : 2500001

    Nantes, 44000, France

  • Investigational Site Number : 2500005

    Brest, Finistère, 29606, France

  • Investigational Site Number : 3920001

    Obihiro, Hokkaido, 080-0013, Japan

  • Investigational Site Number : 3920003

    Kyoto, 606-8507, Japan

  • Investigational Site Number : 3920004

    Matsudo, 271-0092, Japan

  • Investigational Site Number : 5280001

    Bergen op Zoom, North Brabant, 4624 VT, Netherlands

  • Investigational Site Number : 5280002

    Hoofddorp, North Holland, 2134 TM, Netherlands

  • Las Vegas Dermatology- Site Number : 8400027

    Las Vegas, Nevada, 89144-0518, United States

  • Medical Dermatology Specialists Site Number : 8400005

    Phoenix, Arizona, 85006-2754, United States

  • Medical University of South Carolina (MUSC) - PPDS- Site Number : 8400001

    Charleston, South Carolina, 29425-8903, United States

  • Mission Dermatology - Rancho Santa Margarita- Site Number : 8400015

    Rancho Santa Margarita, California, 92688-3623, United States

  • North Texas Center for Clinical Research- Site Number : 8400012

    Frisco, Texas, 75034, United States

  • Oakland Hills Dermatology - 3400 Auburn Rd- Site Number : 8400007

    Auburn Hills, Michigan, 48326-3396, United States

  • Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024

    Phoenix, Arizona, 85008-3884, United States

  • Texas Tech University Health Sciences Center-125 W Hague Rd- Site Number : 8400010

    Lubbock, Texas, 79430-0002, United States

  • Total Vein And Skin, LLC- Site Number : 8400019

    Boynton Beach, Florida, 33437-3782, United States

  • U.S. Dermatology Partners Lee's Summit- Site Number : 8400016

    Lee's Summit, Missouri, 64064, United States

  • U.S. Dermatology Partners Longview- Site Number : 8400032

    Longview, Texas, 75601, United States

  • University of Nebraska - Lauritzen Outpatient Center- Site Number : 8400029

    Omaha, Nebraska, 68105-1026, United States

  • Vivida Dermatology - Flamingo- Site Number : 8400013

    Las Vegas, Nevada, 89119, United States

  • West Virginia Research Institute- Site Number : 8400030

    Morgantown, West Virginia, 26505-1873, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.